]>
IRCT20150704023055N2 IRCT 2020-04-03 Babol University of Medical Sciences Hemoperfusion in patients with COVID-19 To evaluate the effectiveness of hemoperfusion in patients with severe coronavirus disease 2019 (COVID-19) 2020-03-24 anticipated 10 Complete https://irct.ir/trial/46837 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 2 Condition 1: COVID-19. Condition 2: COVID-19. Intervention group: Patients undergo extracorporeal blood purification on three sessions. Each session conducts in six hours per day, using hemoperfusion filters (HA280 and HA230) manufactured by the Jafron Company, China. The second course of hemoperfusion is performed 12-24 hours after the first and the third session 24 hours after the second time.. No - There is not a plan to make this available Justification or reason for not sharing IPD is Information on the clinical features of patients, without mentioning their individual characteristics, will be published through the final report of the study.
public Masoumeh Asgharpour
Ganjafrooz avenue, Babol
Babol Iran (Islamic Republic of) ۴۷۱۷۶۴۷۷۴۵ +98 11 3219 7667 masi9932002@yahoo.com Babol University of Medical Sciences scientific Masoumeh Asgharpour
Ganjafrooz avenue, Babol
Babol Iran (Islamic Republic of) ۴۷۱۷۶۴۷۷۴۵ +98 11 3219 7667 masi9932002@yahoo.com Babol University of Medical Sciences Iran (Islamic Republic of) Patients with diagnosis of COVID-19 based on the clinical manifestations, lung CT-scan, testing of pharyngeal sample using real-time polymerase chain reaction and the physician´s diagnosis Patients who have partial pressure of oxygen in alveoli (PaO2) less than 60, even after different methods of oxygen-therapy Patients who have partial pressure of oxygen in alveoli to the fraction of inspired oxygen (PaO2/FiO2) less than 200 Patients who have partial pressure of carbon dioxide in alveoli (PaCo2) more than 50; PH less than 7.35; peripheral capillary oxygen saturation (SpO2) less than 88%; and no improvement has been achieved despite 48 hours of non-invasive respiratory therapy 18 years no limit Both Plasma platelet count less than 30000 per microliter Multiple organ dysfunction U07.1 U07.2 U07.1: COVID-19, virus identified U07.2: COVID-19, virus not identified Treatment - Other Intervention group: Patients undergo extracorporeal blood purification on three sessions. Each session conducts in six hours per day, using hemoperfusion filters (HA280 and HA230) manufactured by the Jafron Company, China. The second course of hemoperfusion is performed 12-24 hours after the first and the third session 24 hours after the second time. Improving the general condition of the patient. Timepoint: Before intervention and one week after the third session of hemoperfusion. Method of measurement: No need to receive any intensive respiratory care in the patient. Serum level of interleukin- 6. Timepoint: Before the first and after the third session of hemoperfusion. Method of measurement: To test the blood sample. Babol University of Medical Sciences Approved 2020-03-24 Ethics Committee of Babol University of Medical Sciences Ganjafrooz Avenue, Babol Babol Mazandaran Iran (Islamic Republic of)